top of page
Even_header_V22E18AU1-removebg-preview.png
Even_header_V22E18AU1-removebg-preview.png
Leah-Christl-profile.png

Leah Christl, PhD

 

Executive Director, Global Regulatory and R&D Policy, Amgen, USA
 

Dr Christl is currently an Executive Director of Global Regulatory and R&D Policy at Amgen.  She supports Global Biosimilars and serves as the JAPAC Lead. Prior to joining Amgen, Dr Christl served as the Associate Director for Therapeutic Biologics in the Office of New Drugs (OND) in the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). In this role, she developed and led CDER’s approach to implementation of the Biologics Price Competition and Innovation Act (BPCIA) of 2009.  Dr Christl was also the Director of the Therapeutic Biologics and Biosimilars Staff (TBBS) at FDA and served as a scientific, regulatory and policy expert to FDA, HHS, and external stakeholders, on biosimilar products. Dr Christl also engaged in international activities by serving as a CDER and FDA strategist and lead for international activities related to biosimilars, including serving as FDA lead for the FDA-EMA-Health Canada-PMDA biosimilars cluster and the International Pharmaceutical Regulators Programme – Biosimilars Working Group. Dr. Christl received her PhD in Molecular and Cellular Biology and Pathobiology – Marine Biomedicine and Environmental Science from the Medical University of South Carolina in Charleston.

bottom of page